SCHEMBL20695877

SCHEMBL20695877

Cc1cc(C(C)C)ccc1C=O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 2/20 0.66
LMNA P02545 1/20 0.48
PTPN1 P18031 1/20 0.47
PTGS1 P23219 2/20 0.47
TRPA1 O75762 1/20 0.47
CACNA1C Q13936 1/20 0.47
ALDH1A1 P00352 4/20 0.46
TSHR P16473 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
PKM P14618 1/20 0.42
ERN1 O75460 2/20 0.41
PTGS2 P35354 1/20 0.39
RNASEH1 O60930 1/20 0.38
GRIA1 P42261 1/20 0.38
GRIA2 P42262 1/20 0.38
GRIA3 P42263 1/20 0.38
GRIA4 P48058 1/20 0.38
SCN4A P35499 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14136032 0.86 TYR (0.50) TYRLMNAPTPN1PTGS1TRPA1
SCHEMBL1302119 0.85 TYR (0.58) TYRLMNAPTPN1PTGS1TRPA1
SCHEMBL24581328 0.84 TYR (0.68) TYRLMNAPTPN1PTGS1TRPA1
SCHEMBL29088835 0.83 TYR (0.47) TYRLMNAPTPN1PTGS1TRPA1
SCHEMBL29088838 0.83 TYR (0.47) TYRLMNAPTPN1PTGS1TRPA1
SCHEMBL3174939 0.83 LMNA (0.48) TYRLMNAPTPN1PTGS1TRPA1
SCHEMBL10628161 0.81 TYR (0.54) TYRLMNAPTPN1PTGS1TRPA1
SCHEMBL6197624 0.81 TYR (0.63) TYRLMNAPTPN1PTGS1TRPA1
SCHEMBL24240700 0.81 LMNA (0.47) TYRLMNAPTPN1PTGS1TRPA1
SCHEMBL29974338 0.81 LMNA (0.47) TYRLMNAPTPN1PTGS1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118903276-A Application of herba Herminii composition in preparing product for treating and/or relieving symptoms of long new crown, related product and preparation method thereof 江中药业股份有限公司 2024-11-08 CN claimed
US-20260085253-A1 LILY OF THE VALLEY ODORANT FIRMENICH & CIE (CH) 2026-03-26 US disclosed
EP-4046986-B1 METHOD FOR PRODUCING 2,4-DIALKYLBENZALDEHYDE MITSUBISHI GAS CHEMICAL CO (JP) 2026-03-11 EP disclosed
EP-4667472-A1 COMPOUND, COMPOSITION, MOLDED ARTICLE, AND PRODUCTION METHOD MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2025-12-24 EP disclosed
EP-4230612-B1 ALICYCLIC ALCOHOL, ALICYCLIC ALCOHOL COMPOSITION, AND PERFUME COMPOSITION MITSUBISHI GAS CHEMICAL CO (JP) 2025-12-03 EP disclosed
EP-4594453-A1 LILY OF THE VALLEY ODORANT Firmenich SA (CH) 2025-08-06 EP disclosed
US-12145903-B2 Method for producing 2,4-dialkylbenzaldehyde MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2024-11-19 US disclosed
CN-118903276-A Application of herba Herminii composition in preparing product for treating and/or relieving symptoms of long new crown, related product and preparation method thereof 江中药业股份有限公司 2024-11-08 CN disclosed
WO-2024171881-A1 COMPOUND, COMPOSITION, MOLDED ARTICLE, AND PRODUCTION METHOD 三菱瓦斯化学株式会社 2024-08-22 WO disclosed
US-12024487-B2 Method for producing m-dialkylbenzaldehyde MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2024-07-02 US disclosed
CN-114514217-A Method for producing 2, 4-dialkylbenzaldehyde 三菱瓦斯化学株式会社 2022-05-17 CN disclosed
WO-2022085670-A1 ALICYCLIC ALCOHOL, ALICYCLIC ALCOHOL COMPOSITION, AND PERFUME COMPOSITION 三菱瓦斯化学株式会社 2022-04-28 WO disclosed
CN-114127039-A Method for producing m-dialkylbenzaldehyde 三菱瓦斯化学株式会社 2022-03-01 CN disclosed
EP-3438105-B1 DIARYL- -LACTAM COMPOUND AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF UNIV FUDAN (CN) 2022-01-05 EP disclosed
WO-2021075518-A1 METHOD FOR PRODUCING 2,4-DIALKYLBENZALDEHYDE 三菱瓦斯化学株式会社 2021-04-22 WO disclosed
WO-2021075518-A1 METHOD FOR PRODUCING 2,4-DIALKYLBENZALDEHYDE 三菱瓦斯化学株式会社 2021-04-22 WO disclosed
WO-2021039230-A1 METHOD FOR PRODUCING m-DIALKYLBENZALDEHYDE 三菱瓦斯化学株式会社 2021-03-04 WO disclosed
US-20200392150-A1 Diaryl-B-Lactam Compound and Preparation Method and Pharmaceutical Use Thereof FUDAN UNIVERSITY (CN) 2020-12-17 US disclosed
EP-3272754-B1 IMIDAZOPYRROLIDINONE COMPOUNDS NOVARTIS AG (CH) 2019-05-29 EP disclosed
EP-3438105-A1 DIARYL- -LACTAM COMPOUND AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF Fudan University (CN) 2019-02-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392150-A1 Diaryl-B-Lactam Compound and Preparation Method and Pharmaceutical Use Thereof PEPD, SQLE, BACE1 TYR 4030/4885LMNA 1058/4885PTPN1 2806/4885
US-12145903-B2 Method for producing 2,4-dialkylbenzaldehyde CBR1, AFF1, ALKBH1 TYR 1015/4885LMNA 2736/4885PTPN1 3574/4885
US-20260085253-A1 LILY OF THE VALLEY ODORANT PIR, ALG3, ENY2 TYR 609/4885LMNA 2363/4885PTPN1 1562/4885
US-12024487-B2 Method for producing m-dialkylbenzaldehyde ME1, DIMT1, ME3 TYR 696/4885LMNA 1205/4885PTPN1 2955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.